CN114588194A - Biological component composition for improving blood viscosity and blood vessel embolism - Google Patents

Biological component composition for improving blood viscosity and blood vessel embolism Download PDF

Info

Publication number
CN114588194A
CN114588194A CN202210199790.5A CN202210199790A CN114588194A CN 114588194 A CN114588194 A CN 114588194A CN 202210199790 A CN202210199790 A CN 202210199790A CN 114588194 A CN114588194 A CN 114588194A
Authority
CN
China
Prior art keywords
parts
blood
blood viscosity
raw materials
biological component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210199790.5A
Other languages
Chinese (zh)
Inventor
崔晓廷
王悦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Yaoda Biotechnology Co ltd
Original Assignee
Shenyang Yaoda Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Yaoda Biotechnology Co ltd filed Critical Shenyang Yaoda Biotechnology Co ltd
Priority to CN202210199790.5A priority Critical patent/CN114588194A/en
Publication of CN114588194A publication Critical patent/CN114588194A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/20—Aceraceae (Maple family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
    • A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the technical field of medicine and health care products, and discloses a biological component composition for improving blood viscosity and vascular embolism, which comprises the following active component raw materials in parts by weight: 1-20 parts of acer truncatum buge oil microcapsule powder, 1-20 parts of earthworm extract, 1-20 parts of natto, 0.1-5 parts of astaxanthin (haematococcus pluvialis), 0.1-1 part of yeast beta-glucan, 0.02-1.2 parts of vitamin C, 0.5-6 parts of astragalus and angelica extract and auxiliary materials accounting for 0-20% of the total weight of the active ingredient raw materials, wherein the proportion of the astragalus and the angelica in the astragalus and angelica extract is 1:1, and the auxiliary materials can be one or more of cereal starch, potato starch, dextrin and sugar alcohol. The biological component composition for improving the blood viscosity and the vascular embolism has the advantages of obviously reducing serum cholesterol and triglyceride, reducing blood pressure, enhancing the blood supply of heart and brain, softening blood vessels, reducing platelet aggregation and the like, and solves the problems of the blood viscosity and the vascular embolism.

Description

Biological component composition for improving blood viscosity and blood vessel embolism
Technical Field
The invention relates to the technical field of medicine and health care products, in particular to a biological component composition for improving blood viscosity and vascular embolism.
Background
The term "blood viscosity" is medically called hyperviscosity. The blood viscosity is one of the important factors for forming the blood flow resistance, the blood circulation is not smooth, the blood flow speed is reduced, the blood cells can be overlapped and gathered, and the peripheral blood vessel blockage is easily formed. Many diseases are related to blood viscosity, and people with cardiovascular and cerebrovascular diseases have blood viscosity which is several times higher than that of normal people, and often the indexes of blood rheology are abnormal before no obvious clinical symptoms exist. It is known that hypertension, hyperglycemia, hyperlipidemia and hyperglycemia are high risk factors for inducing cardiovascular and cerebrovascular diseases, and the harm of blood viscosity to health is no less than 'four high', improving blood viscosity, preventing and treating the formation of vascular embolism, which has very important significance for early treatment of cardiovascular and cerebrovascular diseases.
The phenomenon of blocking the lumen of a blood vessel by abnormal substances insoluble in blood appearing in circulating blood and traveling to a distant place with the blood flow is called embolism, and common types of embolism include thromboembolism, lipoembolism and the like. The main cause of vascular embolism is hyperviscosity. Blood becomes sticky, thick and coagulated, which leads to insufficient blood supply of coronary artery and arteriosclerosis of blood vessels, so that blood in the blood vessels is coagulated, the blood vessels are plugged into lumens, blood flow cannot pass through the lumens, and the blood vessels are plugged. The vascular embolism can cause ischemia necrosis of blood supply organs, and cause the occurrence of myocardial infarction and cerebral infarction diseases, thereby endangering life and health.
At present, the reduction of blood viscosity mainly adopts a physical dilution method and a drug therapy method, wherein the former method is to introduce a certain amount of liquid medicine into blood vessels to dilute blood so as to reduce the blood viscosity, and the dilution method can quickly reduce the blood viscosity, but the curative effect retention time is short, and the treatment is troublesome; the latter is oral administration of various Chinese and western medicines such as nicotinic acid medicine, and most oral medicines can not achieve satisfactory curative effect. Therefore, it is necessary to develop new products effective in reducing blood viscosity and improving vascular embolization.
Therefore, the invention discloses a biological component composition for improving blood viscosity and vascular embolism, which can obviously reduce serum cholesterol and triglyceride, reduce blood pressure, enhance the blood supply of heart and brain, soften blood vessels and reduce platelet aggregation, thereby reducing or avoiding the generation of blood viscosity and vascular embolism.
Through literature search, products which are identical or similar to the patent in terms of formula, preparation method and application are not reported.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a biological component composition for improving blood viscosity and blood vessel embolism, which has the advantages of remarkably reducing serum cholesterol and triglyceride, lowering blood pressure, enhancing cardio-cerebral blood supply, softening blood vessels, reducing platelet aggregation and the like, and solves the problems of blood viscosity and blood vessel embolism.
(II) technical scheme
In order to achieve the purpose, the invention provides the following technical scheme: a biological component composition for improving blood viscosity and blood vessel embolism comprises the following active component raw materials in parts by weight according to daily dosage: 1-20 parts of acer truncatum buge oil microcapsule powder, 1-20 parts of earthworm extract, 1-20 parts of natto, 0.1-5 parts of astaxanthin (haematococcus pluvialis), 0.1-1 part of yeast beta-glucan, 0.02-1.2 parts of vitamin C, 0.5-6 parts of astragalus root and angelica sinensis extract, and also comprises auxiliary materials accounting for 0-20 percent of the total weight of the active ingredient raw materials, and the oral preparation is prepared by a specific process.
Preferably, in the astragalus mongholicus and angelica sinensis extract, the crude drug ratio of the astragalus mongholicus to the angelica sinensis is 1:1.
Preferably, the raw materials are purchased from commercial raw materials except for the self-made acer truncatum seed oil microcapsule powder, the astragalus mongholicus and angelica sinensis extract and the earthworm extract, and the quality of the raw materials meets the requirements of national relevant food standards or Chinese pharmacopoeia.
Preferably, the auxiliary material can be one or more of cereal starch, potato starch, dextrin and sugar alcohol.
Preferably, the raw materials are purchased from commercial raw materials except for the acer truncatum seed oil microcapsule powder, the astragalus mongholicus and angelica sinensis extract and the earthworm extract, and are qualified according to standard inspection and have the particle size of 100 meshes.
Preferably, the oral preparation includes, but is not limited to, solid beverage, tablet, capsule, liquid beverage.
Preferably, the application is in improving blood viscosity and blood vessel embolism.
Preferably, it is used in improving blood viscosity and other blood rheological parameters, chronic arterial embolism and chronic deep vein embolism.
The biological component combination formula for improving blood viscosity and blood vessel embolism is determined by taking the traditional Chinese medicine and modern biotechnology theories as guidance on the basis of laboratory research and experimental population, and the basic basis of the formula is as follows:
1. acer truncatum seed oil microcapsule powder
Acer truncatum seed oil contains unsaturated fatty acid more than 90%, nearly hundreds of natural nutrients such as oleic acid, linolenic acid and the like beneficial to human body, and particularly contains about 5.5% of natural cis-15-tetracosenic acid. Cis-15-tetracosenic acid is the only one double-effect miraculous substance which is recognized by scientists in various countries and can repair and dredge damaged nerve fibers and promote nerve cell regeneration. The growth factor can promote growth of the growth factor, has the functions of nourishing, repairing, regenerating and remodeling nerve cells, can protect vascular endothelium, repair vascular variant cells and necrosis factors, block deposition of blood peroxide on vascular walls and plaque formation, can treat heart and brain simultaneously, and has irreplaceable remarkable effect on blood viscosity and complicating cardiovascular and cerebrovascular diseases. The invention adopts acer truncatum seed oil microcapsule powder instead of new food raw material nervonic acid, because nervonic acid is a synthetic compound, the nervonic acid can have synthetic conditions at present, few production plants obtaining production permission are provided, the detection method is not clear and uniform, and a lot of nervonic acid water goods and fake goods are sold on the market, so that the quality of the raw materials is difficult to ensure. In addition, the synthesized nervonic acid does not contain other rich natural components except cis-15-tetracosenoic acid in acer truncatum seed oil, and in contrast, acer truncatum seed oil and the microcapsule powder prepared from the acer truncatum seed oil are beneficial and are a characteristic of raw material selection.
2. Earthworm extract
The invention adopts earthworm (Eisenia foetida) to prepare the earthworm extract by extraction, concentration, drying and sterilization. Earthworm protein is not adopted because the earthworm protein is mainly protein (protein is more than or equal to 65 percent, lumbrokinase cannot be detected) and does not contain other components except the protein in the earthworm, and the effect is far less than that of the earthworm extract through the verification of a comparative test. The extract of earthworm prepared by a specific process preserves the components of plasmin, lumbrokinase, collagenase, nucleic acid, trace elements and the like contained in the earthworm. Has effects in inhibiting platelet aggregation, promoting thrombolysis, improving microcirculation and collateral circulation of blood vessel, and increasing blood flow. Has definite biological activity for improving blood rheology index, coronary heart disease, angina pectoris, cerebral infarction, etc. The earthworm extract is also a feature of the raw material selection of the invention.
3. Natto
The soybean is prepared by fermenting with bacillus subtilis. Contains rich nutrients such as saponin, isoflavone, enzymes, viable Bacillus natto, unsaturated fatty acid, lecithin, folic acid, calcium, ferrum, potassium, vitamins, various amino acids, minerals, etc. Especially contains special components of nattokinase and vitamin K2, and researches prove that the natto has the health-care effects of dissolving thrombus, resisting inflammation, resisting bacteria, resisting aging and regulating physiological functions. The product can also be prepared by fermenting bean micropowder with Bacillus subtilis.
4. Astaxanthin
Astaxanthin is a carotenoid from haematococcus pluvialis, is 'antioxidative king' (6000 times of VC) in the nature, can penetrate through cell membranes and blood brain barriers, can remove free radicals, can reduce cholesterol, can protect blood vessels and nerves, and plays a vital role in resisting oxidative stress of cardiovascular and cerebrovascular systems.
5. Yeast beta-glucans
The saccharomyces cerevisiae is used as a raw material and is produced by extraction, acid-base treatment, spray drying and the like. Natural and safe, and high bioactivity. Has effects in resisting radiation, neutralizing chemical toxin, removing toxin, regulating blood lipid, preventing coronary heart disease, arteriosclerosis, apoplexy, resisting tumor, hepatitis B virus, rheumatic disease, autoimmune disease, regulating blood sugar, and protecting and repairing pancreatic islet beta-cell. Can provide multiple cell growth factors and repair the damaged cells of blood vessels.
6. Vitamin C
Can remove super negative oxygen ions, relieve toxic and harmful effects of lead, arsenic, mercury and the like, enhance the anti-stress capability and immunity of the body to the external environment, improve the metabolism of fat, improve the utilization of folic acid, calcium and iron, promote the synthesis of ossein and antibodies, and be beneficial to constructing the healthy intravascular environment.
7. Extract of radix astragali and radix Angelicae sinensis
Radix astragali has effects of invigorating vital qi, strengthening spleen and stomach, and promoting blood circulation. Dang Gui can tonify blood, activate blood, moisten intestines to relieve constipation. The combination of the astragalus root and the angelica with the earthworm in the formula is a wonderful combination. The earthworms have channeling property and can dredge collaterals; radix astragali has effects of invigorating qi, nourishing blood, and promoting qi circulation; the angelica has the effects of promoting blood circulation, removing blood stasis and enriching blood, and the three are matched to enhance the effects of promoting blood circulation, dredging collaterals, tonifying qi and nourishing blood, and has synergistic effect on improving blood viscosity and complicating cardiovascular and cerebrovascular diseases.
Although the raw materials in the formula are used singly and have the functions of adjusting the blood viscosity and the probability of the occurrence of complications to different degrees, the emphasis, the action mechanism, the use amount and the compatibility contraindication of each raw material are different. The formula is determined in the process of a large number of experiments, and the inventor surprisingly discovers that the components have obvious synergistic interaction after the raw materials are compatible for use, and the 1+1>2 effect is generated. High utilization rate of raw materials and obvious effect of improving and adjusting blood viscosity and complicating diseases. Toxicological tests of the formulation also indicate that it is safe.
Compared with the prior art, the invention provides a biological component composition for improving blood viscosity and vascular embolism, and the biological component composition has the following beneficial effects:
1. the biological component combination for improving blood viscosity and blood vessel embolism is a four-in-one scientific formula consisting of an antioxidant component, an anticoagulant component, a fibrinolytic component and a qi and blood tonifying component, has four efficacies of clearing (removing blood rubbish), regulating (regulating high risk factors of cardiovascular and cerebrovascular diseases), dissolving (tracing and dissolving thrombus) and tonifying (activating blood and tonifying qi), improves blood viscosity in multiple ways and multiple mechanisms, prevents and treats blood vessel embolism, is scientific and unique in formula, has broken tonifying effect, clear mechanism, synergistic effect and prominent comprehensive function, fundamentally improves blood viscosity and blood vessel embolism, and has substantial novelty and creativity compared with the prior art.
2. The biological component combination for improving blood viscosity and blood vessel embolism has definite effect on improving blood coagulation, viscosity and thickening, has actual effect on chronic arterial embolism and chronic deep venous embolism, provides a barrier for reducing the incidence of coronary heart disease and cerebral apoplexy, has substantial technical progress, and has great significance for human health.
3. The biological component composition for improving blood viscosity and vascular embolism has the advantages of large market demand, easily available raw materials, dual purposes of medicine and food, high use safety, simple preparation process and no need of more investment, and the implementation of the technical scheme has good economic benefit and social benefit.
(III) detailed description of the preferred embodiments
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
Example one
This example is a specific embodiment of a combination of biological components to improve blood viscosity and vascular embolization.
A biological component composition for improving blood viscosity and blood vessel embolism comprises the following active component raw materials in parts by weight according to daily dosage: 1-20 parts of acer truncatum buge oil microcapsule powder, 1-20 parts of earthworm extract, 1-20 parts of natto, 0.1-5 parts of astaxanthin (haematococcus pluvialis), 0.1-1 part of yeast beta-glucan, 0.02-1.2 parts of vitamin C, 0.5-6 parts of astragalus root and angelica sinensis extract, and also comprises auxiliary materials accounting for 0-20 percent of the total weight of the active ingredient raw materials, and the oral preparation is prepared by a specific process.
Specifically, in the astragalus and angelica extract, the crude drug ratio of the astragalus to the angelica is 1:1.
Specifically, the raw materials except the acer truncatum seed oil microcapsule powder, the astragalus mongholicus and angelica sinensis extract and the earthworm extract are self-prepared and are purchased from commercial raw materials, and the quality of the raw materials meets the requirements of national relevant food standards or Chinese pharmacopoeia.
Specifically, the adjuvants can be one or more of cereal starch, potato starch, dextrin, and sugar alcohol.
Specifically, the raw materials except the acer truncatum seed oil microcapsule powder, the astragalus mongholicus and angelica sinensis extract and the earthworm extract are self-prepared and are all purchased from commercial raw materials, and the raw materials are qualified according to standard inspection and have the particle size of 100 meshes.
In particular, oral formulations include, but are not limited to, solid beverages, tablets, capsules, liquid beverages.
In particular to the application in improving blood viscosity and blood vessel embolism.
In particular, it is applied to improving blood viscosity and other blood rheological parameters, chronic arterial embolism and chronic deep vein embolism.
Example two
This example is a specific implementation of an optimized protocol for the combination of biological components to improve blood viscosity and vascular embolization.
An optimized scheme of biological component combination for improving blood viscosity and vascular embolism comprises the following active component raw materials in parts by weight according to daily dosage: 2.8-3 parts of acer truncatum buge oil microcapsule powder, 1.7-2.3 parts of earthworm extract, 1.5-2 parts of natto, 0.4-0.5 part of astaxanthin (haematococcus pluvialis), 0.1-0.2 part of yeast beta-glucan, 0.1-0.2 part of vitamin C, 1.9-2 parts of astragalus mongholicus and angelica sinensis extract and also comprises auxiliary materials accounting for 0-20 percent of the total weight of the active ingredient raw materials, and the oral preparation is prepared by a specific process.
EXAMPLE III
This example is a more suitable embodiment of a combination of biological components to improve blood viscosity and vascular embolization.
The scheme is characterized by comprising the following active ingredient raw materials in parts by weight according to daily dosage: 2 parts of acer truncatum buge oil microcapsule powder, 2.2 parts of earthworm extract, 2 parts of natto, 0.5 part of astaxanthin (haematococcus pluvialis), 0.25 part of yeast beta-glucan, 0.2 part of vitamin C, 1.85 parts of astragalus mongholicus and angelica sinensis extract, and also comprises auxiliary materials accounting for 0-20% of the total weight of active ingredient raw materials, and the oral preparation is prepared by a specific process.
Example four
This example is a specific implementation of the preparation method of acer truncatum seed oil microcapsule powder.
The preparation method of the acer truncatum seed oil microcapsule powder comprises the following steps:
s1, weighing the modified starch and water according to the proportion of 1:1.5, and adding the modified starch and water into normal-temperature water for dissolving to form modified starch slurry;
s2, weighing the acer truncatum seed oil and the modified starch according to the ratio of 1:1.5, adding the acer truncatum seed oil and the modified starch into the modified starch slurry, and carrying out high-speed shearing for 10 minutes at the rotating speed of a shearing machine (17000 r/min);
s3, placing the sheared emulsion into a homogenizer, homogenizing for 2 times under the pressure of the homogenizer (10kpa/c square meter) to obtain homogenized emulsion, drying the homogenized emulsion at the temperature of below 50 ℃, and crushing to obtain the acer truncatum seed oil microcapsule powder.
EXAMPLE five
This example is a specific embodiment of the method for preparing the extract of astragalus and angelicae sinensis.
The preparation method of the astragalus and angelica extract comprises the following steps:
s1, crushing astragalus and angelica into 20 meshes, and soaking the crushed astragalus and angelica in 70% ethanol in an amount which is 8 times that of the crushed angelica for 4 hours;
s2, heating, refluxing and extracting for 2 times, wherein each time is 1.5 hours, and the temperature is 70 ℃;
s3, mixing the filtrates, recovering ethanol, concentrating the precipitate to 1.15, oven drying at below 70 deg.C, and pulverizing.
EXAMPLE six
This example is a specific embodiment of a method for producing an earthworm extract.
The preparation method of the earthworm extract comprises the following steps:
s1, cleaning earthworms, and removing impurities from the earthworms and cleaning;
s2, breaking the wall of the earthworms, soaking the cleaned earthworms in normal saline with the volume ratio of the earthworms to the normal saline being 1:1.5-2, breaking the wall of the earthworms after soaking for 20-30 minutes, and filtering to remove the horny layer of the earthworms to obtain earthworm liquid; removing salt from the earthworm liquid through a permeable membrane;
s3, extracting, namely adding acetic acid solution into the earthworm liquid, fully mixing the earthworm liquid and the acetic acid solution according to the volume ratio of 1:2-3 to obtain mixed liquid, extracting for 30 minutes, controlling the temperature to be 60 ℃, and filtering filtrate;
s4, concentrating, performing rotary evaporation on the mixed solution, and concentrating to obtain a concentrated solution;
s5, drying, and drying the concentrated solution to obtain extract powder;
s6, sterilizing, and sterilizing the extract powder to obtain the edible earthworm extract.
EXAMPLE seven
The embodiment is a specific implementation mode of a preparation method of a solid beverage preparation of biological component combination for improving blood viscosity and blood vessel embolism.
A preparation method of a solid beverage preparation of a biological component combination for improving blood viscosity and blood vessel embolism comprises the following steps:
s1, the weight portions of the following raw materials are:
2.8kg of acer truncatum buge oil microcapsule powder, 1.7kg of earthworm extract, 1.5kg of natto, 0.4-kg of astaxanthin (haematococcus pluvialis), 0.1kg of yeast beta-glucan, 0.1kg of vitamin C, 1.9kg of astragalus mongholicus and angelica sinensis extract and 1.5kg of corn starch.
S2, the preparation method comprises the following steps: weighing raw materials, mixing for 1 hour, drying at 60 deg.C to water content of less than or equal to 5%, packaging, inspecting, packaging, and warehousing.
Example eight
This example is a specific embodiment of a method for preparing a tablet formulation of a combination of biological ingredients for improving blood viscosity and vascular embolization.
A preparation method of a tablet preparation of a biological component combination for improving blood viscosity and blood vessel embolism comprises the following steps:
s1, the weight portions of the following raw materials are:
3kg of acer truncatum buge oil microcapsule powder, 2.3kg of earthworm extract, 2kg of natto, 0.5kg of astaxanthin (haematococcus pluvialis), 0.2kg of yeast beta-glucan, 0.2kg of vitamin C, 2kg of astragalus mongholicus and angelica sinensis extract and 0.2kg of corn starch;
s2, the preparation method comprises the following steps: the raw materials are qualified through inspection, weighed, mixed for 1 hour, granulated by 16 meshes, dried at the temperature of 60 ℃ to ensure that the moisture is less than or equal to 5 percent, pressed into tablets, dried in the air, subpackaged, inspected, packaged and warehoused to obtain the finished product.
Example nine
This example is a specific embodiment of a method for preparing a capsule containing a combination of biological ingredients for improving blood viscosity and vascular embolization.
A preparation method of a tablet capsule preparation of biological component combination for improving blood viscosity and blood vessel embolism comprises the following steps:
the weight portions of the following raw materials are as follows:
s1, 2kg of acer truncatum oil microcapsule powder, 2.2kg of earthworm extract, 2kg of natto, 0.5kg of astaxanthin (haematococcus pluvialis), 0.25kg of yeast beta-glucan, 0.2kg of vitamin C, 1.85 kg of astragalus and angelica extract and 1kg of corn starch;
s2, the preparation method comprises the following steps: the raw materials are qualified by inspection, weighed, mixed for 1 hour, granulated by 16 meshes, dried at the temperature of 60 ℃ to ensure that the water content is less than or equal to 5 percent, filled into capsules, subpackaged, inspected, packaged and warehoused to obtain the capsule.
Example ten
This example is a specific embodiment of a method for preparing a liquid beverage formulation with a combination of biological ingredients that improves blood viscosity and vascular embolization.
A method for preparing a liquid beverage preparation containing a combination of biological components for improving blood viscosity and blood vessel embolism comprises the following steps:
s1, weighing and mixing the formula raw materials, and adding 90% of purified water;
s2, stirring, packaging, sterilizing, and making into liquid beverage.
Examples of the experiments
The product for improving blood viscosity and blood vessel embolism reduces the blood viscosity and improves the effect record of complications.
Tracking the number of observed people: 20 of the Chinese patent medicines: 8 men and 12 women, age 44-78 years.
Tracking and observing conditions: the past history of hypertension, hyperlipidemia, hyperglycemia, coronary heart disease and cerebral apoplexy with blood hyperviscosity and complication is 3-5 years, and a hospital has a diagnostic book within one year.
The treatment method comprises the following steps: the product of example 4 was used, one bag per day; the administration is continued for 20-72 days and the results are recorded.
Tracking follow-up visit: for the test persons to follow up one by one, the detailed inquiry, physical examination and examination of the detection report within 10 days are carried out, and the following follow-up results are as follows:
statistical result of follow-up visit for experimental case tracking
Figure BDA0003527083540000101
Figure BDA0003527083540000111
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims (8)

1. A biological component composition for improving blood viscosity and blood vessel embolism is characterized in that: the composition comprises the following active ingredient raw materials in parts by weight: 1-20 parts of acer truncatum buge oil microcapsule powder, 1-20 parts of earthworm extract, 1-20 parts of natto, 0.1-5 parts of astaxanthin (haematococcus pluvialis), 0.1-1 part of yeast beta-glucan, 0.02-1.2 parts of vitamin C, 0.5-6 parts of astragalus root and angelica sinensis extract, and also comprises auxiliary materials accounting for 0-20 percent of the total weight of the active ingredient raw materials, and the oral preparation is prepared by a specific process.
2. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: in the astragalus and angelica extract, the crude drug ratio of the astragalus to the angelica is 1:1.
3. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: the raw materials are self-prepared except for acer truncatum seed oil microcapsule powder, astragalus mongholicus and angelica sinensis extract and earthworm extract, are purchased from commercial raw materials, and the quality of the raw materials meets the requirements of national relevant food standards or Chinese pharmacopoeia.
4. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: the adjuvants can be one or more of cereal starch, potato starch, dextrin, and sugar alcohol.
5. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: the raw materials are all purchased from commercial raw materials except for acer truncatum seed oil microcapsule powder, astragalus mongholicus and angelica sinensis extract and earthworm extract, and are qualified according to standard inspection and have the particle size of 100 meshes.
6. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: the oral preparation includes but is not limited to solid beverage, tablet, capsule and liquid beverage.
7. The biological component combination for improving blood viscosity and blood vessel embolism according to claim 1, wherein: is applied to improving blood viscosity and blood vessel embolism.
8. The combination of biological components for improving blood viscosity and vascular embolization according to claim 1, wherein: it is used in improving blood viscosity and other blood rheological parameters, chronic arterial embolism and chronic deep vein embolism.
CN202210199790.5A 2022-03-01 2022-03-01 Biological component composition for improving blood viscosity and blood vessel embolism Pending CN114588194A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210199790.5A CN114588194A (en) 2022-03-01 2022-03-01 Biological component composition for improving blood viscosity and blood vessel embolism

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210199790.5A CN114588194A (en) 2022-03-01 2022-03-01 Biological component composition for improving blood viscosity and blood vessel embolism

Publications (1)

Publication Number Publication Date
CN114588194A true CN114588194A (en) 2022-06-07

Family

ID=81814766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210199790.5A Pending CN114588194A (en) 2022-03-01 2022-03-01 Biological component composition for improving blood viscosity and blood vessel embolism

Country Status (1)

Country Link
CN (1) CN114588194A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102406115A (en) * 2011-10-26 2012-04-11 江苏江大源生态生物科技有限公司 Natural functional food for preventing cardiovascular and cerebrovascular diseases
CN108310044A (en) * 2018-03-26 2018-07-24 刘莹艳 A kind of Chinese medicine of relaxing tendons and activating collaterals and preparation method thereof
CN109645295A (en) * 2019-01-17 2019-04-19 云南龙布瑞生物科技有限公司 A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102406115A (en) * 2011-10-26 2012-04-11 江苏江大源生态生物科技有限公司 Natural functional food for preventing cardiovascular and cerebrovascular diseases
CN108310044A (en) * 2018-03-26 2018-07-24 刘莹艳 A kind of Chinese medicine of relaxing tendons and activating collaterals and preparation method thereof
CN109645295A (en) * 2019-01-17 2019-04-19 云南龙布瑞生物科技有限公司 A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
聂克: "黄芪当归药对对心血管系统作用的研究概况", 《中国中西医结合杂志》 *

Similar Documents

Publication Publication Date Title
US8927523B2 (en) Compound sea cucumber preparation and manufacturing method thereof
US20170128514A1 (en) Pharmaceutical composition for treating cardio-cerebrovascular diseases and method for preparing the same
CN101724667A (en) Technology for extracting dendrobium polysaccharide by applying biology engineering enzyme technology and product thereof and application
CN107184966A (en) A kind of pharmaceutical composition for preventing and treating diabetes and its complication
CN112961262A (en) Passiflora edulis pericarp acidic polysaccharide, preparation method and application thereof
CN105341893A (en) Composition for assisting in reducing blood glucose and application
CN104857154A (en) Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor
CN101664180A (en) Health-care nutritional complexing agent with effect of and preparation method thereof
CN111743924A (en) Marine plant extract for treating diabetes, composition and application
CN106362142A (en) Formula composition capable of reducing blood pressure
CN106509894A (en) Moringa oleifera and pseudo-ginseng buccal tablets and preparation technology thereof
CN114588194A (en) Biological component composition for improving blood viscosity and blood vessel embolism
CN104922295A (en) Blood-nourishing and blood-enriching traditional Chinese medicine composition
CN105433260A (en) Health-care food for reducing blood fat and preparation process thereof
CN107927764A (en) A kind of health food containing sea cucumber extract and earthworm albumen powder and preparation method thereof
AU2021100051A4 (en) Antitumor formula and extraction method thereof
CN111000237A (en) Dietary composition for dietary intervention of cardiovascular and cerebrovascular diseases and preparation method thereof
CN110638988A (en) Preparation method of plant cell zymolyte for killing human herpes zoster virus
CN111729056A (en) Anticancer medicine composition and its prepn
CN103494978B (en) Method for preparing freeze-dried powder injection for treating liver ascitic tumor by using aloe and lucid ganoderma
CN108420842A (en) A kind of sowthistle-leaf ixeris seedling preparation of antigout effect
CN103055011A (en) G6 lectin extracted from traditional Chinese medicines and applications thereof in detoxification, pressure stabilization, blood vessel softening and complication resistance
CN113491331B (en) Algal polysaccharide composition and compound fruit juice mixed fermentation powder as well as preparation method and application thereof
CN108452047B (en) Composition for delaying senility, inhibiting growth of tumor cells and improving cardiovascular and cerebrovascular microcirculation
CN107412607B (en) Asparagus capsule and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220607

WD01 Invention patent application deemed withdrawn after publication